Neurocrine Biosciences (NBIX) Free Cash Flow Growth (3y) (2013 - 2026)
Neurocrine Biosciences (NBIX) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | 14.41% |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 216.31% |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 4.08% |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 49.44% |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | -10.40% |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | -9.38% |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 134.18% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Alkermes | 8.19 Bn | 7.53 Bn | 397.90 Mn | -12.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.38% |
| Mar 31, 2026 | 46.56% |
| Dec 31, 2025 | 35.52% |
| Sep 30, 2025 | 31.44% |
| Jun 30, 2025 | -7.50% |
| Mar 31, 2025 | 48.12% |
| Dec 31, 2024 | 257.36% |
| Sep 30, 2024 | 48.01% |
| Jun 30, 2024 | -10.49% |
| Mar 31, 2024 | 10.95% |
| Dec 31, 2023 | 12.90% |
| Sep 30, 2023 | 130.75% |
| Jun 30, 2023 | 14.73% |
| Mar 31, 2023 | -77.85% |
| Dec 31, 2022 | 13.14% |
| Sep 30, 2022 | -0.70% |
| Jun 30, 2022 | 29.88% |
| Mar 31, 2022 | 27.39% |
| Dec 31, 2021 | -29.48% |
| Sep 30, 2021 | -12.37% |